Equities

Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)21.63
  • Today's Change0.12 / 0.56%
  • Shares traded961.79k
  • 1 Year change-16.71%
  • Beta0.8430
Data delayed at least 15 minutes, as of Nov 13 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Sep 30 2023202320222021
ASSETS
Cash And Short Term Investments396376368
Total Receivables, Net01.4110
Total Inventory------
Prepaid expenses8.817.294.36
Other current assets, total15202.19
Total current assets420405385
Property, plant & equipment, net33616966
Goodwill, net------
Intangibles, net101214
Long term investments0106246
Note receivable - long term------
Other long term assets0.210.220.27
Total assets766692710
LIABILITIES
Accounts payable362.879.46
Accrued expenses686226
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total1.3074111
Total current liabilities105139147
Total long term debt000
Total debt000
Deferred income tax------
Minority interest1620--
Other liabilities, total373135155
Total liabilities494293301
SHAREHOLDERS EQUITY
Common stock0.200.200.20
Additional paid-in capital1,3001,2191,053
Retained earnings (accumulated deficit)(1026)(821)(645)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(3.22)(0.14)(0.07)
Total equity271399409
Total liabilities & shareholders' equity766692710
Total common shares outstanding107106104
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.